PMID- 12925816 OWN - NLM STAT- MEDLINE DCOM- 20031216 LR - 20171101 IS - 0301-1569 (Print) IS - 0301-1569 (Linking) VI - 65 IP - 3 DP - 2003 May-Jun TI - Comparison of the protective efficacy of neurotrophins and antioxidants for vibration-induced trauma. PG - 155-61 AB - BACKGROUND: Patients undergoing temporal bone surgery or subjects working with vibrating tools may develop vibration-induced hearing loss (VHL). The aim of this study was to characterize the effects of pretreatment with N-acetylcysteine (NAC) or the neurotrophic factors, brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF), on VHL in an animal model. METHODS: Trauma to the cochlea was created with a vibrating probe placed on the bone of the external ear canal. BDNF and CNTF(Ax1) were delivered into the cochlea with mini-osmotic pumps. NAC was delivered into the cochlea by round window membrane (RWM) injection, by RWM permeation, or by oral administration. Hearing was evaluated with electrocochleography (ECoG). RESULTS: For control animals, vibration resulted in an average immediate threshold shift of 42 +/- 26 dB. NAC provided no protective benefit in animals subjected to VHL, regardless of the delivery method, with average threshold shifts varying from 38 to 56 dB across groups. NAC injection through the round window membrane was toxic, causing a ECoG threshold shift of >25 dB. In BDNF+CNTF(Ax1)-treated animals, immediate hearing loss was similar to that in control animals. There was a trend of threshold recovery by 1 day after vibration; however, the improvement was not statistically significant, nor was there a significant difference in 1-day thresholds across groups. CONCLUSIONS: Local infusion of BDNF and CNTF(Ax1) may enhance the rate of recovery from VHL, compared to control animals. In contrast, NAC had no effect on VHL, and when delivered by RWM injection, was actually toxic to the inner ear. CI - Copyright 2003 S. Karger AG, Basel FAU - Zou, Jing AU - Zou J AD - Department of Otolaryngology, Tampere University Hospital, Teiskontie 35, FI-33521 Tampere, Finland. FAU - Bretlau, Poul AU - Bretlau P FAU - Pyykko, Ilmari AU - Pyykko I FAU - Toppila, Esko AU - Toppila E FAU - Olovius, N Petri AU - Olovius NP FAU - Stephanson, Niklas AU - Stephanson N FAU - Beck, Olof AU - Beck O FAU - Miller, Josef M AU - Miller JM LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Switzerland TA - ORL J Otorhinolaryngol Relat Spec JT - ORL; journal for oto-rhino-laryngology and its related specialties JID - 0334721 RN - 0 (Antioxidants) RN - 0 (Nerve Growth Factors) RN - 0 (Neuroprotective Agents) SB - IM MH - Animals MH - Antioxidants/*pharmacology MH - Audiometry, Evoked Response MH - Auditory Threshold/drug effects MH - Endolymph/metabolism MH - Guinea Pigs MH - Hair Cells, Auditory/drug effects MH - Hearing Loss, Sensorineural/etiology/*physiopathology/*prevention & control MH - Nerve Growth Factors/metabolism/*pharmacology MH - Neuroprotective Agents/*pharmacology MH - Vibration EDAT- 2003/08/20 05:00 MHDA- 2003/12/17 05:00 CRDT- 2003/08/20 05:00 PHST- 2002/10/18 00:00 [received] PHST- 2003/04/25 00:00 [accepted] PHST- 2003/08/20 05:00 [pubmed] PHST- 2003/12/17 05:00 [medline] PHST- 2003/08/20 05:00 [entrez] AID - 72253 [pii] AID - 10.1159/000072253 [doi] PST - ppublish SO - ORL J Otorhinolaryngol Relat Spec. 2003 May-Jun;65(3):155-61. doi: 10.1159/000072253.